Delving into the Latest Updates on Henan Furen Medicines Group Co. Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

以中国健康受试者为对象，研究辅仁药业集团有限公司生产的米诺膦酸片（受试制剂，规格：1 mg/片）与小野药品工业株式会社生产的米诺膦酸片（参比制剂，Recalbon，规格：1 mg/片）的药代动力学特征，评价空腹条件下单次服药（1 mg）的人体生物等效性。

[Translation]

Methods: The pharmacokinetic characteristics of minodronic acid tablets (test preparation, strength: 1 mg/tablet) produced by Furen Pharmaceutical Group Co., Ltd. and minodronic acid tablets (reference preparation, Recalbon, strength: 1 mg/tablet) produced by Ono Pharmaceutical Co., Ltd. were studied in healthy Chinese subjects, and the bioequivalence of a single dose (1 mg) under fasting conditions was evaluated.

Start Date-

Sponsor / Collaborator

Furen Medicines Group Co., Ltd.

[+1]

CTR20190579

/ Not yet recruitingNot Applicable

咪达那新片开放、随机、单次给药、两周期、两序列、自身交叉试验

[Translation] An open, randomized, single-dose, two-period, two-sequence, self-crossover trial of imidacin tablets

以中国健康受试者为对象，考察河南辅仁堂制药有限公司研制的咪达那新片（受试制剂，0.1 mg/片）与小野药品工业株式会社生产的咪达那新片（参比制剂，STAYBLA，0.1 mg/片）的药代动力学特征，分别评价空腹和餐后条件下单次给药（0.1 mg）后的生物等效性。

[Translation]

Methods: The pharmacokinetic characteristics of imidafenacin tablets (test preparation, 0.1 mg/tablet) developed by Henan Fu Ren Tang Pharmaceutical Co., Ltd. and imidafenacin tablets (reference preparation, STAYBLA, 0.1 mg/tablet) produced by Ono Pharmaceutical Co., Ltd. were investigated in healthy Chinese subjects, and the bioequivalence after a single dose (0.1 mg) under fasting and fed conditions was evaluated.

Start Date-

Sponsor / Collaborator

Furen Medicines Group Co., Ltd.

[+2]

CTR20190575

/ Not yet recruitingNot Applicable

阿齐沙坦片开放、随机、单次给药、两周期、两序列、自身交叉试验

[Translation] An open-label, randomized, single-dose, two-period, two-sequence, self-crossover trial of azilsartan tablets

试验目的以中国健康受试者为对象，考察开封制药（集团）有限公司研制的阿齐沙坦片（受试制剂，20 mg/片）与日本武田药品工业株式会社生产的阿齐沙坦片（参比制剂，AZILVA，20 mg/片）的药代动力学特征，分别评价空腹和餐后条件下单次给药（20 mg）后的生物等效性。

[Translation]

Purpose: To investigate the pharmacokinetic characteristics of Azilsartan Tablets (test preparation, 20 mg/tablet) developed by Kaifeng Pharmaceutical (Group) Co., Ltd. and Azilsartan Tablets (reference preparation, AZILVA, 20 mg/tablet) produced by Takeda Pharmaceutical Company Limited in China using healthy subjects as subjects, and to evaluate the bioequivalence after a single dose (20 mg) under fasting and fed conditions, respectively.

Start Date-

Sponsor / Collaborator

Kaifeng Pharmaceutical (Group) Co., Ltd.

[+1]

100 Clinical Results associated with Henan Furen Medicines Group Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Henan Furen Medicines Group Co. Ltd.

Login to view more data

100 Deals associated with Henan Furen Medicines Group Co. Ltd.

Login to view more data

100 Translational Medicine associated with Henan Furen Medicines Group Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data